Evidence map›Paper›PMID 17337766›Full record

ReviewImmunologic research2006

Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization.

Jonathan D Steckbeck, Kelly Stefano Cole

Abstract readReview
In one paragraph

Review in Immunologic research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jonathan D SteckbeckDepartment of Medicine, Infectious Diseases Division, University of Pittsburgh School of Medicine, Pittsburgh PA 15261, USA.
Kelly Stefano Cole

Funding

Mechanisms of SIV NeutralizationR01AI052058 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI COLE, KELLY STEFANO · 2002 to 2005
$1.2M
NIAID NIH HHS R01 AI052058
6 · The paper itself

Abstract

The ultimate goal of an AIDS vaccine is to elicit potent cellular and humoral immune responses that will result in broadly enduring protective immunity. During the past several years, we have focused on characterizing the quantitative and qualitative properties of the antibody response, principally working to define the mechanism(s) of antibody-mediated neutralization in vitro. We have utilized a panel of monoclonal antibodies generated from monkeys infected with attenuated SIV for more than 8 mo to dissect the early events of virus infection involved in antibody-mediated neutralization. Presented herein are highlights from our studies that have identified potential mechanisms by which antibodies neutralize SIV in vitro.

Indexed as

AIDS VaccinesAnimalsAntibodies, MonoclonalAntibodies, ViralAntibody AffinityBinding Sites, AntibodyHIVHIV Envelope Protein gp120HumansMacaca mulattaNeutralization TestsSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAIDS VaccinesAntibodies, MonoclonalAntibodies, ViralHIV Envelope Protein gp120SAIDS Vaccines

Identifiers

PMID17337766
PMCPMC3357918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.